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Abstract We have developed a method that we call ‘drug-sen-
sitivity pattern analysis’, or DSPA, for analysis of protein func-
tion. Cells are transfected with cDNA of the test molecule,
followed by analysis of the sensitivity of the transfected cells
to multiple growth-inhibitory drugs. If two cDNA products have
similar functions, their transfected cells should show similar
drug-sensitivity patterns. The cDNAs of some signaling mole-
cules were transfected into NIH3T3 or Ha-ras-transformed
NIH3T3 (ras-NIH) cells and stable transfectants, which ex-
pressed high amounts of the gene product, were isolated. Che-
mosensitivity of the transfected clone was compared with the
parental cells by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylte-
trazolium bromide method using more than 40 drugs. The che-
mosensitivity changes caused by the transfected gene were cal-
culated and expressed numerically as ‘drug chemosensitivity
index’ (DCI). When the DCI values were analyzed by regression
analysis, a signi¢cant positive relationship between IUBK super-
repressor and dominant-negative IKKL and an inverse relation-
ship between p53 and Mdm2 were consistent with previous re-
ports. Thus, the DSPA method is useful for identifying
functional similarities between gene products.
4 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The ability to analyze the function of gene products may be
one of the main challenges of biological research in the post-
genomic era. The current methods for analyzing protein func-
tion are exempli¢ed by yeast two-hybrid systems, GST pull-
down assays and the TAP method [1] as a probe for binding
proteins, and by di¡erential display and DNA microarray to
investigate changes in gene expression. Such methods are la-
borious, time-consuming, and expensive. Development of sim-
ple methods for analysis of protein function has been ex-
pected.
Functional analysis can also be studied in cultured cells by
transfection followed by induction of the expression of the test
cDNA. However, without remarkable changes in cell growth
or morphology, one does not know how intracellular molec-
ular events have been in£uenced by the transfected cDNA.
We have reported that activated Ha-ras-transformed
NIH3T3 (ras-NIH) cells have di¡erent sensitivities to anti-
cancer drugs [2]. The patterns of sensitivity were similar to
those of Ki-ras-transformed cells but di¡erent from v-src- or
c-erbB2-transformed cells. We hypothesize that the changes in
drug sensitivity of cells transfected by genes may produce a
speci¢c pattern, depending upon the function of the gene
products. Analysis of the drug-sensitivity pattern (DSPA),
following transfection by genes, may be useful for predicting
the functional similarity of gene products.
2. Materials and methods
2.1. Cell culture
NIH3T3, ras-NIH and their transfected cells [3] were cultured in
Dulbecco’s modi¢ed Eagle’s medium supplemented with 5% calf se-
rum.
2.2. Transfection
The cDNAs were inserted into eukaryotic expression vectors
pcDNA3, pRc-CMV (Invitrogen) or pMSG (Amersham Pharmacia)
and transfected into NIH3T3 or ras-NIH cells using Lipofectamine
reagent (Invitrogen) as previously described [4^6]. After culture in the
presence of G418 (400 Wg/ml) for 2 weeks, surviving colonies were
isolated.
2.3. MTT assay
Five thousand cells per well were plated in 96-well plates in the
presence of various concentrations of test drugs, and cultured for
3 days. The activity of mitochondrial succinic dehydrogenase was
measured by incubation for 4 h in the presence of 0.5 mg/ml of
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(Sigma). Absorbance was measured at 570 nm with a reference wave-
length of 655 nm according to the method of Mosmann [7], using
previously described methods [8]. Absorbance re£ects the viable cell
number and was expressed as a percentage of that of cells cultured in
the absence of test drugs.
2.4. Preparation of cell extract and immunoblotting analysis
Cells were washed with phosphate-bu¡ered saline three times and
incubated in lysis bu¡er [0.5% Nonidet P-40, 20 mM Tris^HCl (pH
7.5), 1 mM EDTA, 1 mM phenylmethylsulfonyl £uoride, 50 WM leu-
peptin, 50 WM antipain, 50 WM pepstatin A and 50 WM N-acetyl-Leu-
Leu-norleucinal (ALLN)] for 10 min at 4‡C. The cell lysate was cen-
trifuged at 13 000Ug for 10 min and the resulting supernatant was
lyophilized. Immunoblot analysis was carried out using Immunostar
(Wako Pure Chemicals, Kyoto, Japan) as described previously [9].
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The antibody used was phospho-speci¢c extracellular signal-regulated
kinase (ERK) antibody (Santa Cruz Biotechnology).
3. Results and discussion
3.1. Competence of MTT assay for analysis of chemosensitivity
The cDNAs were constructed in eukaryotic expression vec-
tors and transfected into NIH3T3 or ras-NIH cells using
Lipofectamine. Transfected cells were selected by culture in
the presence of 400 Wg/ml of G418 for 2 weeks. Clones that
expressed the highest level of the cDNA-encoded protein, as
analyzed by immunoblotting, were used in the MTT assay.
Sensitivities to at least 40 drugs (Table 1) were examined by
Mosmann’s MTT assay [7]. Because the MTT assay was
highly reproducible, duplicate assays were su⁄cient to deter-
mine the sensitivity. The sensitivity of ras-NIH cells to wort-
mannin was almost the same when examined on di¡erent days
(Fig. 1a). A similar overlap in the sensitivity to cisplatin be-
tween ras-NIH and STAT1-transfected ras-NIH cells was also
observed (Fig. 1b). High expression of STAT1 caused no ap-
parent e¡ect on the sensitivity to cisplatin. In contrast, trans-
fection of wild-type p53 into ras-NIH cells reduced the sensi-
tivity to sodium arsenite (Fig. 1c).
A concentration of drug that gave 40% inhibition, the turn-
ing point for most of the sigmoid curves, was used to quanti-
tate the di¡erence of the chemosensitivity from the results of
MTT assays (Fig. 1c). Then, the ratios of the drug con-
centrations giving 40% inhibition in a test cDNA-introduced
clone (IC40test) versus those in the parental cells (IC40parent)
were calculated. The logarithmic values of the ratios
(log(IC40test/IC40parent)), designated drug chemosensitivity
index (DCI), were entered into the database, partly shown
in Table 2. The DSPA is based on comparison of the regres-
sion analysis of the DCI values of transfected cells by conven-
tional statistical software. If signi¢cant correlation was ob-
served for any two transfectants, it is likely that the gene
products of the transfected cDNA were functionally similar.
3.2. DSPA for cells transfected with cDNAs encoding both
functionally similar and functionally di¡erent proteins
Fig. 2a shows the distribution pattern between p53- and
p21/cip1-transfected ras-NIH cells. Each point represents the
DCI value of a single drug in the transfected cells shown on
the ordinate and abscissa. The correlation coe⁄cient (r) was
0.56 (P6 0.001), indicating that DCI values of p53- and p21-
transfected cells were signi¢cantly correlated. These data are
consistent with the previous report that p53 transactivates p21
and thereby suppresses cell proliferation [10]. The DCI values
of p53-transfected cells were negatively correlated with those
of wild-type Mdm2-transfected cells, but positively correlated
with those of mutant Mdm2-transfected cells (Fig. 2b,c). The
mutant Mdm2 was unable to associate with p53 [11]. Mdm2 is
induced by activated p53, but the high expression of Mdm2
stimulates degradation of p53 protein [12,13]. Because Mdm2
Table 1
List of drugs
Drug name Primary activity or classi¢cation
Herbimycin A Src, Abl kinase inhibitor
Geldanamycin Src kinase inhibitor; hsp90 inhibitor
Erbstatin EGFR inhibitor
Genistein tyrosine kinase inhibitor, topoisomerase II
inhibitor
Le£unomide tyrosine kinase inhibitor
Staurosporine PKC, cdk, MLCK inhibitor
K252a CaM-kinase inhibitor
KN-93 CaM-kinase inhibitor
H-7 PKA, PKC, PKG inhibitor
H-8 PKG, PKA inhibitor
GF109203X PKC inhibitor
ML-7 MLCK inhibitor
Y-27632 ROCK inhibitor
Olomoucine cdk inhibitor
3-ATA cdk4 inhibitor
Okadaic acid PP1, PP2A inhibitor
Cantharidin PP2A inhibitor
Sodium vanadate tyrosine phosphatase inhibitor
Sodium arsenite tyrosine phosphatase inhibitor
Mitomycin C DNA cross-linker
5-Fluorouracil thymidine synthetase inhibitor
Cisplatin DNA cross-linker
Methotrexate DHFR inhibitor
Mitoxantrone DNA strand breaker
Aclarubicin DNA intercalator
Ifosfamide DNA alkylation
Hydroxyurea ribonucleotide reductase inhibitor
6-Thioguanine purine metabolism inhibitor
Camptothecin topoisomerase I inhibitor
Peplomycin DNA strand breaker
Vincristine microtubule depolymerizer
Taxol microtubule inhibitor
Etoposide topoisomerase II inhibitor
Pi¢thrin p53 inhibitor
BAY 11-7085 NF-UB inhibitor
Parthenolide NF-UB inhibitor
HA14-1 Bcl-2 inhibitor
Ac-Leu-Leu-leucinal calpain/proteasome inhibitor
ONO-3403 trypsin inhibitor
ONO-5046 elastase inhibitor
TPCK chymotrypsin inhibitor
ICE inhibitor III caspase inhibitor
Wortmannin PI3K inhibitor
Quercetin PI3K inhibitor
Manumycin farnesyltransferase inhibitor
Cytochalasin D actin polymerization inhibitor
Ouabain Naþ,Kþ-ATPase inhibitor
SAHA histone deacetylase inhibitor
Sirtinol deacetylase inhibitor
Telomerase inhibitor
VIII
telomerase inhibitor
A23187 Ca2þ ionophore
BAPTA-AM Ca2þ chelator
Thapsigargin Ca2þ-ATPase inhibitor
Oligomycin mitochondrial ATPase inhibitor
U73122 phospholipase C inhibitor
DFMO ornithine decarboxylase inhibitor
SnPP heme oxygenase inhibitor
Curcumin 5-lipoxygenase and cyclooxygenase inhibitor
NorNOHA arginase inhibitor
5-AIQ PARP inhibitor
Forskolin adenylate cyclase activator
MDL-12,330A adenylate cyclase inhibitor
NS2028 guanylate cyclase inhibitor
IBMX phosphodiesterase inhibitor
Cycloheximide protein synthesis inhibitor
Anisomycin protein synthesis inhibitor
SNAP NO donor
Resveratrol COX1 inhibitor, ribonucleotide reductase
inhibitor
Sulindac COX inhibitor
Table 1 (Continued).
Drug name Primary activity or classi¢cation
Indomethacin COX1/2 inhibitor, phospholipase A2 inhibitor
Sodium azide cytochrome a/a3 binding
Rapamycin immunosuppressant
Betulinic acid anti-HIV
C8-ceramide apoptosis inducer
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Table 2
The DCIs of transfected cells
Stauro-
sporine
K252a H-7 Y-27632 HMA Genistein Erbstatin Okadaic
acid
Cant-
haridin
ALLN ONO-
3403
ONO-
5046
U73122 BAPTA-
AM
A23187 NaAsO2
p53 0.07 0.05 0.00 0.30 30.22 0.26 0.17 30.05 0.30 0.18 0.04 0.09 0.11 0.00 0.30 0.20
p21/Cip1 0.00 30.11 0.22 0.00 30.30 0.02 0.06 30.15 0.00 0.18 0.04 30.14 0.08 0.00 0.04 0.30
Mdm2-wt 0.02 30.17 0.02 30.10 30.08 30.06 0.03 30.02 0.08 30.08 0.00 0.03 0.18 0.08 0.14 0.02
Mdm2-mutant 30.16 30.09 0.05 0.16 30.17 30.14 0.03 30.09 30.11 0.38 0.05 30.45 0.00 30.03 0.00 30.33
IUB-SR 0.32 0.00 0.30 0.00 30.14 30.05 0.60 0.25 0.24 0.10 0.47 0.07 0.00 0.00 0.20 0.14
IKK-DN 0.32 0.02 0.25 0.21 30.18 0.25 0.63 0.15 0.30 0.00 0.17 0.02 30.09 0.00 0.00 0.05
p16/INK4A 30.22 30.22 0.08 0.16 0.41 0.40 0.51 0.06 0.16 0.09 0.29 0.22 0.28 0.20 0.00 0.16
HSP40 0.30 0.07 0.15 0.22 0.00 0.00 0.00 30.02 30.16 0.18 0.17 30.15 30.20 0.05 30.16 30.02
HSP90 0.22 0.56 30.03 0.76 0.40 0.41 0.26 0.07 30.20 0.16 0.36 0.52 0.18 0.60 0.28 0.10
Hsdj 0.50 0.16 0.45 0.32 0.24 0.03 0.23 0.12 0.17 0.12 0.40 0.00 30.24 0.21 0.46 0.03
TERT-WT 0.00 0.00 0.09 0.36 0.08 30.15 30.05 0.03 0.00 0.37 30.37 30.32 0.03 0.32 0.11 30.05
TERT-DN 0.56 0.00 0.28 0.30 0.62 0.18 0.17 30.16 0.14 0.03 0.07 0.32 0.06 0.84 0.59 0.34
Ha-ras 0.30 0.65 0.23 0.31 30.35 30.35 0.08 0.11 30.40 0.15 30.22 0.00 30.19 30.20 30.28 0.04
Ki-ras 0.38 0.15 0.28 0.45 30.14 0.00 0.04 0.04 30.46 0.11 30.30 0.51 30.60 30.15 0.06 0.08
N-ras 0.24 30.16 0.30 0.00 0.43 0.42 30.22 0.00 30.21 0.17 30.17 0.23 30.54 0.00 0.20 30.19
Calpastatin 0.04 0.10 30.14 30.22 30.14 0.13 30.20 30.04 30.04 0.10 0.00 30.10 30.31 0.00 30.12 0.00
ERK-DN 0.06 0.05 0.14 0.00 0.00 0.00 0.13 0.00 30.05 0.00 0.10 0.00 0.00 0.12 0.00 0.16
JNK-DN 0.14 30.28 0.09 0.13 30.14 30.10 0.11 30.07 30.04 30.24 0.22 30.09 30.07 0.06 30.08 30.07
p38-DN 30.05 30.15 0.10 0.00 30.05 0.00 0.06 0.12 0.00 0.04 0.14 30.04 0.00 0.00 30.12 0.00
Calpastatin-AS 30.15 0.00 0.00 30.12 30.10 0.00 0.06 0.13 30.18 0.00 0.00 30.06 30.10 0.06 30.36 0.02
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and p53 cause opposite e¡ects on cell proliferation by direct
interaction, these data are compatible with the expectations of
DSPA.
The activity of transcription factor NF-UB is suppressed by
the binding protein IUB [14]. Phosphorylation of IUB by IKK
results in proteolytic degradation of IUB by proteasome [15].
Thus, a non-phosphorylated IUBK superrepressor mutant,
IUB-SR, and a dominant-negative IKKL mutant, IKK-DN,
can inhibit the activity of NF-UB [16]. The DCI values of
IUB-SR- and IKK-DN-transfected cells were highly correlated
with each other (r=0.75, P6 0.001) (Fig. 2d). On the other
hand, the drug-sensitivity pro¢les of IUB-SR-transfected cells
were totally unrelated to those of p16/INK4A-transfected cells
(Fig. 2e). The fact that there is no evidence for interaction
between p16 and IUB is also consistent with our data. The
DSPA method can therefore discriminate functional unrelat-
edness between two gene products.
We have recently reported that calpastatin, an endogenous
calpain inhibitor, induces anchorage-independent transforma-
tion of NIH3T3 cells [17]. Furthermore, the transformed phe-
Fig. 2. Regression analysis of the DCI values of transfected cells. The DCI values, shown in Table 2, were plotted for two transfected cells.
Transfected cDNAs were (a) p53 and p21, (b) p53 and Mdm2-WT, (c) p53 and Mdm2-mutant, (d) IUB-SR and IKK-DN, (e) IUB-SR and p16,
(f) calpastatin and ERK-DN, (g) calpastatin-antisense (AS) and ERK-DN, and (h) HSP90 and TERT-DN.
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notype of ras-NIH cells was reversed by transfection with
calpastatin antisense (calpastatin-AS) cDNA. The DSPA
showed that the DCI values of calpastatin-transfected
NIH3T3 cells were negatively correlated with those of domi-
nant-negative ERK (ERK-DN)-transfected ras-NIH cells
(r=30.49, P6 0.001; Fig. 2f) and that DCIs of calpastatin-
AS-transfected ras-NIH cells were positively correlated with
those of ERK-DN transfectants (r=0.68, P6 0.001; Fig. 2g).
This suggests that calpastatin expression caused similar e¡ects
to those caused by ERK. When the activated ERKs were
examined by immunoblotting using phospho-speci¢c ERK
antibody, activated ERK3 in addition to ERK1 and ERK2
was detected in calpastatin-transfected cells (Fig. 3). Thus,
DSPA analysis also appears to be useful for predicting the
signaling pathway of the cDNA gene product.
A recent report showed that there is a stable association
between HSP90 and telomerase reverse transcriptase (TERT)
[18]. The good correlation of the DCI values of HSP90-trans-
fected ras-NIH cells with those of dominant-negative TERT-
transfected ras-NIH cells (r=0.53, P6 0.001) con¢rmed this
interaction (Fig. 2h). This results may imply opposite roles
between HSP90 and wild-type TERT.
Correlation coe⁄cients (r) are summarized in Table 3.
When the DCI values were obtained by the analysis of 40
drugs, r values higher than 0.4 or lower than 30.4 represent
statistical signi¢cance (P6 0.01). r values higher than 0.5 or
lower than 30.5 show even higher signi¢cance (P6 0.001).
These signi¢cant relations are di¡erentially shown in color.
It may be impossible to con¢rm all of the results of Table 3
at present. However, there are no data thus far to contradict
the ¢ndings of DSPA. Based on the DSPA results, some of
Fig. 3. Expression of activated ERKs in calpastatin-transfected
NIH3T3 cells. Cytoplasmic cell extracts of NIH3T3 (NIH) and its
calpastatin transfectant (calpast) were analyzed by immunoblotting
using phospho-speci¢c ERK antibody which recognized activated
ERKs. Arrows indicate the positions of activated ERKs (P-ERK1,
P-ERK2 and P-ERK3).
Table 3
Correlation of DCI values of transfected cells by DSPA
Correlation coe⁄cients (r) obtained by DSPA are summarized. Signi¢cant relations are shown in color as indicated.
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the functional molecular interactions around p53 are shown in
Fig. 4. It allowed us to predict the signaling network centered
by p53.
3.3. Advantages and limitations of DSPA
DSPA is a new method for comprehensive analysis of gene
products with many advantages. (i) Functional similarities
between the test cDNA and all other genes listed in the data-
base have been revealed only by addition of the DCI values of
the test-cDNA-transfected cells. (ii) By using the DSPA meth-
od, functional similarity of gene products can be predicted in
the absence of protein manipulation. (iii) The estimation of
the functional similarity does not simply re£ect characteristics
associated with cell growth or survival. (iv) There are techni-
cal advantages to DSPA. Speci¢cally, the experimental peri-
ods for analysis are short. The inexpensive and technically
simple MTT assay can be ¢nished within 2 weeks and requires
no special equipment. Routine protocols produce reproducible
results. The data are not in£uenced by operator bias. (v) The
DSPA is available for analysis of post-translational modi¢ers
such as kinases and proteases. The relationship of signaling
pathways a¡ected by the transfected genes can also be
studied; the DSPA points to functional similarities among
proteins of the same gene family (e.g. Ha-ras, Ki-ras and
N-ras), binding proteins (p53 and Mdm2, HSP90 and
TERT), transcription factors and their target genes (p53 and
p21), and enzymes and the substrates.
The DSPA also has some limitations. (i) DSPA data might
be meaningful only in the cell system that is being used. For
example, the results of our study in mouse ¢broblasts may not
be reliably extrapolated to other cell systems. With a large
database that incorporates a variety of cells, such as embry-
onic, epidermal, neuronal, and hematopoietic, utility could be
dramatically expanded. (ii) Another problem would exist if
the cDNA gene products are not e¡ective in regulation of
cell viability. It may also be di⁄cult to discern the functional
relationships of the molecules that are not directly involved in
cell growth or survival. However, most of signaling pathways
are interrelated, and direct, as well as indirect, e¡ects on
branch pathways may impact cell viability. (iii) The DSPA
system may, in some cases, require analysis of multiple, rather
than single, independent transfectants. For example, most of
the cells transfected with growth-inhibitory molecules were
unable to form G418-resistant colonies. Nevertheless, some
clones grew because of secondary changes that suppressed
the signaling. These secondary changes which may account
for the clonal variation could be related to the transfected
gene, and also be identi¢ed by DSPA. (iv) A signi¢cant in-
verse correlation is not necessarily observed between the wild-
type and dominant-negative mutant forms of a molecule. The
expression of the dominant-negative form may not cause ef-
fects, particularly when the endogenous activity of the wild-
type is low. On the other hand, if the endogenous activity is
already high, overexpression of the wild-type molecule may
have little e¡ect.
As a further application, DSPA can potentially be used to
study the mechanism of action of bioactive chemical com-
pounds. Transfection with dominant-negative mutants produ-
ces signi¢cant results as shown in Fig. 2c,d,h. If hypothetical
drug X can inhibit hypothetical enzyme Y, the cells trans-
fected with the dominant-negative form of the enzyme will
have the same DCI values as the cells treated with drug X.
Thus, the drug-treated cells can also be used instead of trans-
fected cells. This application may be particularly important
because it will facilitate recognition of unexpected side e¡ects
of newly developed drugs.
These data, taken together, indicate that molecular relation-
ships suggested by DSPA have enormous potential for future
application and provide direction for new investigations. The
DSPA method is a potentially useful primary strategy that is
rapid, simple and convenient for study of functional relation-
ship between gene products.
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